OnKure Therapeutics, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Biotechnology Value Fund L.P. amended its Schedule 13G filing on OnKure Therapeutics, Inc., updating its beneficial ownership stake in the clinical-stage biotech. The amendment was disclosed in an SEC filing under accession number 0000921895-26-003184. Schedule 13G amendments are typically filed by passive investors to reflect changes in holdings, though the filing summary did not specify the exact percentage or share count. The update matters because it signals a shift in institutional ownership for OnKure, a company whose investor base can influence trading liquidity and sentiment. Investors will watch for the full filing details to confirm whether the fund increased, trimmed or maintained its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
OnKure Therapeutics, Inc., BIOTECHNOLOGY VALUE FUND L P